{"id":"W4235951270","doi":"10.3747/co.26.4096","title":"Perspectives on treatment advances for stage III locally advanced unresectable non-small-cell lung cancer","year":2019,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"U.S. Food and Drug Administration; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Durvalumab; Medicine; Oncology; Lung cancer; Radiation therapy; Internal medicine; Chemotherapy; Stage (stratigraphy); Clinical trial; Cancer; Immunotherapy; Nivolumab","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002589505,0.0004766465,0.0007113141,0.0008177933,0.0003233335,0.001263124,0.0007288842,0.00129744,0.003466984],"category_scores_gemma":[0.002260608,0.0001223502,0.0009024049,0.0005584595,0.0005492365,0.002350391,0.0005516518,0.003870788,0.001313944],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001058045,"about_ca_system_score_gemma":0.001515379,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009291556,"about_ca_topic_score_gemma":0.003987664,"domain_scores_codex":[0.999495,0.0001729957,0.00007443726,0.00006443937,0.000141037,0.00005200514],"domain_scores_gemma":[0.9985639,0.0007367815,0.0001386383,0.00003260906,0.0003813384,0.0001466712],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"systematic_review","study_design_scores_codex":[0.0002453105,0.0001286181,0.0005383729,0.005715707,0.0001190763,0.0003887745,0.0001089883,0.0006178536,0.00201845,0.01061126,0.1177189,0.8617887],"study_design_scores_gemma":[0.00006657564,0.000362406,0.00106563,0.003381788,0.0001439232,0.0009765191,0.0001212547,0.0002194315,0.000427105,0.005009389,0.988205,0.00002106664],"study_design_candidate":"systematic_review","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0004086453,0.9747002,0.0004504746,0.01986871,0.002214909,0.000009129007,0.00004590285,0.00001768599,0.00228438],"genre_scores_gemma":[0.003738813,0.9789191,0.001168815,0.009596999,0.005018809,0.00001963292,0.0000998353,0.000009967276,0.001427895],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003466984,"threshold_uncertainty_score":0.01369482,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04177159213969803,"score_gpt":0.4109122224770908,"score_spread":0.3691406303373927,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}